Skip to main content
. 2023 Aug 2;35(1):33–41. doi: 10.1007/s10552-023-01760-5

Table 2.

Number of diagnoses, age at first primary neoplasm (FPN) for all sampled cases and controls (including backup controls), age at subsequent primary neoplasms (SPN) and latency between first and subsequent primary neoplasm in years for all sampled cases; by first neoplasm*

First neoplasm N Cases Controlsa Total
Age in years at FPN diagnosis Age in years at SPN diagnosis Latency (y) to SPN N Age in years at FPN diagnosis
Mean (Min–Max) Mean (Min–Max) Mean (Min–Max) Mean (Min–Max)
Lymphoid leukemia 377 5.6 (0–14) 17.4 (2–41) 11.7 (0.6–33.1) 1660 5.7 (0–14) 2037
Acute myeloid leukemia 55 6.9 (0–14) 16.5 (2–41) 9.8 (0.6–27.3) 216 6.6 (0–14) 271
Other leukemia 13 7.2 (1–14) 18.5 (3–32) 11.3 (0.7–28.4) 32 8.4 (0–14) 45
Hodgkin ‘s disease 127 11.3 (3–14) 27.7 (5–46) 16.3 (0.8–32.8) 395 11.0 (2–14) 522
Non-Hodgkin ‘s disease 100 7.8 (0–14) 19.7 (1–43) 11.8 (0.5–30.1) 369 8.5 (1–14) 469
Other lymphomas 0 ** ** ** 10 7.2 (0–14) 10
Non-malignant CNS-tumors 33 7.4 (0–14) 18.2 (3–37) 10.8 (1.0–25.3) 335 7.4 (0–14) 368
Malignant CNS-tumors 195 5.7 (0–14) 17.5 (1–40) 11.8 (0.5–30.4) 437 6.7 (0–14) 632
Neuroblastomas 67 2.3 (0–13) 11.2 (1–35) 8.9 (1.1–30.6) 259 1.9 (0–14) 326
Retinoblastomas 33 0.7 (0–5) 12.5 (2–29) 11.7 (2.5–28.7) 138 1.4 (0–8) 171
Renal tumors 43 4.2 (0–13) 18.5 (4–40) 14.3 (0.7–32.3) 345 3.7 (0–14) 388
Liver tumors 4 ** ** 7.4 (2.2–18.0) 27 2.4 (0–14) 31
Bone tumors 60 10.5 (5–14) 19.9 (8–39) 9.4 (0.6–24.7) 223 10.6 (0–14) 283
Soft tissue sarcomas 91 5.6 (0–14) 16.6 (2–41) 11.0 (1.2–31.9) 288 6.8 (0–14) 379
Germ cell tumors 35 8.3 (0–14) 21.2 (2–40) 13.0 (1.6–28.5) 190 7.2 (0–14) 225
Thyroid carcinomas 1 ** ** ** 25 10.4 (5–14) 26
Skin tumors incl. Malignant Melanoma 1 ** ** ** 6 9.0 (5–13) 7
Other tumors 9 8.7 (0–14) 18.3 (2–41) 9.6 (0.6–28.5) 21 9.0 (1–14) 30
Total 1244 6.5 (0–14) 18.4 (1–46) 11.9 (0.5–33.1) 4976 6.5 (0–14) 6220

CNS central nervous system, SPN subsequent primary neoplasm, y years, N number of cases

*Inclusion criteria for cases and controls: age at diagnosis of first neoplasm below 15, year of diagnosis of first neoplasm between 1980 and 2014, resident in Germany at the time of both the diagnosis of the first and second neoplasm, minimum latency between first and subsequent neoplasm: 0.5 years

**No results given as the number of patients was below 5

aSome patients were selected as case and as control for a different case (whose SPN occurred later in terms of age at diagnosis). Such individuals can account for multiple diagnosed tumors in this table, which have occurred at different periods in their lives